'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis

Journal of Hepatology

Volumn 44, Issue 6, 2006, Pages 1196-1207

  Lonardo, Amedeo ^a   Carani, Cesare ^a   Carulli, Nicola ^a   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANDROGEN; ANGIOTENSIN II; ASPARTYL AMINOPEPTIDASE; ESTROGEN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; INCRETIN; INSULIN; LEPTIN; LEVOTHYROXINE; LOSARTAN; PANCREAS HORMONE; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THYROID HORMONE; THYROXINE;

ACROMEGALY; ADRENAL CORTEX; CUSHING SYNDROME; GLUCOSE TOLERANCE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE METABOLISM; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOGONADISM; HYPOPITUITARISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; INSULIN BINDING; INSULIN RELEASE; LIPODYSTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ORCHIECTOMY; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ENDOCRINE SYSTEM; FATTY LIVER; HORMONES; HUMANS; MICE;

EID: 33646128472     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.03.005     Document Type: Review

References (192)

1. Ludwig J., Viggiano T., McGill D., and Ott B. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980) 434-438
2. Park S.H., Kim B.I., Yun J.W., Kim J.W., Park D.I., Cho Y.K., et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 19 (2004) 694-698
3. Loria P., Lonardo A., and Carulli N. Should nonalcoholic fatty liver disease be renamed?. Dig Dis 23 (2005) 72-82
4. Loria P., Lonardo A., Carulli L., Verrone A.M., Ricchi M., Lombardini S., et al. Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 22 (2005) 31-36
5. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
6. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 115 (2005) 1111-1119
7. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353 (2005) 1711-1723
8. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115 (2005) 911-919
9. Norrelund H. Consequences of growth hormone deficiency for intermediary metabolism and effects of replacement. Front Horm Res 33 (2005) 103-120
10. Johannson G., Marin P., Johannson J.O., and Bengtsson B.A. Growth hormone and syndrome. In: Smith R.G., and Thorner M.E. (Eds). Human growth hormone: research and clinical practice (2000), Humana Press, Totowa, NJ 247-260
11. Murray R.D. The phenotype of adults with partial growth hormone deficiency. Horm Res 64 (2005) 12-17
12. Sesti G., Sciacqua A., Cardellini M., Marini M.A., Maio R., Vatrano M., et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28 (2005) 120-125
13. Hayes F.J., Fiad T.M., and McKenna T.J. Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy. Metabolism 48 (1999) 308-313
14. Sesmilo G., Biller B.M., Llevadot J., Hayden D., Hanson G., Rifai N., et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133 (2000) 111-122
15. Adams L.A., Feldstein A., Lindor K.D., and Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39 (2004) 909-914
16. Nakajima K., Hashimoto E., Kaneda H., Tokushige K., Shiratori K., Hizuka N., et al. Pediatric nonalcoholic steatohepatitis associated with hypopituitarism. J Gastroenterol 40 (2005) 312-315
17. Takano S., Kanzaki S., Sato M., Kubo T., and Seino Y. Effect of growth hormone on fatty liver in panhypopituitarism. Arch Dis Child 76 (1997) 537-538
18. Kaji H., Sakurai T., Iguchi G., Murata M., Kishimoto M., Yoshioka S., et al. Adult growth hormone deficiency in Japan: results of investigation by questionnaire. Endocr J 49 (2002) 597-604
19. Ichikawa T., Hamasaki K., Ishikawa H., Ejima E., Eguchi K., and Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 52 (2003) 914
20. Lonardo A., Loria P., Leonardi F., Ganazzi D., and Carulli N. Growth hormone plasma levels in nonalcoholic fatty liver disease. Am J Gastroenterol 97 (2002) 1071-1072
21. Leung K.C., Johannsson G., Leong G.M., and Ho K.K. Estrogen regulation of growth hormone action. Endocr Rev 25 (2004) 693-721
22. Wiesli P., Bernays R., Brandle M., Zwimpfer C., Seiler H., Zapf J., et al. Effect of pituitary surgery in patients with acromegaly on adiponectin serum concentrations and alanine aminotransferase activity. Clin Chim Acta 352 (2005) 175-181
23. Viguerie N., and Langin D. Effect of thyroid hormone on gene expression. Curr Opin Clin Nutr Metab Care 6 (2003) 377-381
24. Caldwell S.H., Chang C.Y., Nakamoto R.K., and Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 595-617
25. Lonardo A., et al. Insulin resistance in NAFLD: a clinical perspective. In: Leuschner U., et al. (Ed). Steatohepatitis (NASH and ASH) (2001), Kluwer, Dordrecht 104-113
26. Janan J., Bodi L., Agota G., Bardos L., Rudas P., Kozak J., et al. Relationships between force-feeding and some physiological parameters in geese bred for fatty liver. Acta Vet Hung 48 (2000) 89-97
27. Liangpunsakul S., and Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?. J Clin Gastroenterol 37 (2003) 340-343
28. Lin S.Y., Wang Y.Y., Liu P.H., Lai W.A., and Sheu W.H. Lower serum free thyroxine levels are associated with metabolic syndrome in a Chinese population. Metabolism 54 (2005) 1524-1528
29. Shulman A.I., and Mangelsdorf D.J. Retinoid X Receptor heterodimers in the metabolic syndrome. N Engl J Med 353 (2005) 604-615
30. Bellassoued M., Mnif M., Kaffel N., Rekik N., Rebai T., Tahri N., et al. Thyrotoxicosis hepatitis: a case report. Ann Endocrinol 62 (2001) 235-238
31. Sasaki K., Cripe T.P., Koch S.R., Andreone T.L., Petersen D.D., Beale E.G., et al. Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription: the dominant role of insulin. J Biol Chem 259 (1984) 15242-15251
32. Hargrove J.L., and Granner D.K. Biosynthesis and intracellular processing of tyrosine aminotransferases. In: Christen P., and Metzler D.E. (Eds). Transaminases (1985), Wiley, New York 511-532
33. Meisner H., Loose D.S., and Hanson R.W. Effect of hormones on transcription of the gene for cytosolic phosphoenolpyruvate carboxykinase (GTP) in rat kidney. Biochemistry 24 (1985) 421-425
34. Rizza R.A., Mandarino L.J., and Gerich J.E. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54 (1982) 131-138
35. Rooney D.P., Neely R.D., Cullen C., Ennis C.N., Sheridan B., Atkinson A.B., et al. The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. J Clin Endocrinol Metab 77 (1993) 1180-1183
36. Delaunay F., Khan A., Cintra A., Davani B., Ling Z.C., Andersson A., et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 100 (1997) 2094-2098
37. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities?. Obes Rev 2 (2001) 73-86
38. Watts L.M., Manchem V.P., Leedom T.A., Rivard A.L., McKay R.A., Bao D., et al. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54 (2005) 1846-1853
39. Buren J., and Eriksson J.W. Is insulin resistance caused by defects in insulin's target cells or by a stressed mind?. Diabetes Metab Res Rev 21 (2005) 487-494
40. Westerbacka J., Yki-Jarvinen H., Vehkavaara S., Hakkinen A.M., Andrew R., Wake D.J., et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 88 (2003) 4924-4931
41. Zoppini G., Targher G., Venturi C., Zamboni C., and Muggeo M. Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clin Endocrinol 61 (2004) 711-715
42. Frederich Jr. R.C., Kahn B.B., Peach M.J., and Flier J.S. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 19 (1992) 339-344
43. Hainault I., Nebout G., Turban S., Ardouin B., Ferre P., and Quignard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab 282 (2002) E59-E66
44. Prat-Larquemin L., Oppert J.M., Clement K., Hainault I., Basdevant A., Guy-Grand B., et al. Adipose angiotensinogen secretion, blood pressure, and AGT M235T polymorphism in obese patients. Obes Res 12 (2004) 556-561
45. Caglayan E., Blaschke F., Takata Y., and Hsueh W.A. Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol 5 (2005) 135-142
46. Yvan-Charvet L., Even P., Bloch-Faure M., Guerre-Millo M., Moustaid-Moussa N., Ferre P., et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54 (2005) 991-999
47. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30 (2004) 498-505
48. Jandeleit-Dahm K.A., Tikellis C., Reid C.M., Johnston C.I., and Cooper M.E. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23 (2005) 463-473
49. Kurtz T.W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42 (2005) S9-S16
50. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
51. Parer S., Jullien Y., Rochette A., and Cuchet D. Acute hepatic steatosis of pregnancy in an Addisonian patient. Ann Fr Anesth Reanim 2 (1983) 296-299
52. Nestler J.E., and McClanahan M.A. Diabetes and adrenal disease. Bailliere Clin Endocrinol Metab 64 (1992) 829-847
53. Oben J.A., Roskams T., Yang S., Lin H., Sinelli N., Torbenson M., et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 53 (2004) 438-445
54. Oben J.A., and Diehl A.M. Sympathetic nervous system regulation of liver repair. Anat Rec A Discov Mol Cell Evol Biol 280 (2004) 874-883
55. Oben J.A., Roskams T., Yang S., Lin H., Sinelli N., Li Z., et al. Induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun 308 (2003) 284-292
56. Li Z., Oben J.A., Yang S., Lin H., Stafford E.A., Soloski M.J., et al. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 40 (2004) 434-441
57. Yokoyama Y., Nimura Y., Nagino M., Bland K.I., and Chudry I.H. Current understanding of gender dimorphism in hepatic pathophysiology. J Surg Res 128 (2005) 147-156
58. Lonardo A., and Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J Gastroenterol Hepatol 15 (2000) 775-782
59. Bacon B.R., Farahvash M.J., Janney C.G., and Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107 (1994) 1103-1109
60. Lonardo A., Bellini M., Tondelli E., Frazzoni M., Grisendi A., Pulvirenti M., et al. Nonalcoholic steatohepatitis and the 'bright liver syndrome': should a recently expanded clinical entity be further expanded?. Am J Gastroenterol 90 (1995) 2072-2074
61. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
62. Sanyal A.J. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 1705-1725
63. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37 (2003) 1202-1219
64. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
65. Ruhl C.E., and Everhart J.E. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 124 (2003) 1821-1829
66. Liangpunsakul S., and Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 329 (2005) 111-116
67. Ioannou G.N., Weiss N.S., Boyko E.J., Kahn S.E., and Lee S.P. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 128 (2005) 627-635
68. Schwimmer J.B., McGreal N., Deutsch R., Finegold M.J., and Lavine J.E. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics 115 (2005) e561-e565
69. Pendino G.M., Mariano A., Surace P., Caserta C.A., Fiorillo M.T., Amante A., et al. ACE Collaborating Group. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 41 (2005) 1151-1159
70. Park H.S., Han J.H., Choi K.M., and Kim S.M. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 82 (2005) 1046-1051
71. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 (2000) 112-117
72. Akahoshi M., Amasaki Y., Soda M., Tominaga T., Ichimaru S., Nakashima E., et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 24 (2001) 337-343
73. Omagari K., Kadokawa Y., Masuda J., Egawa I., Sawa T., Hazama H., et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17 (2002) 1098-1105
74. Shen L., Fan J.G., Shao Y., Zeng M.D., Wang J.R., Luo G.H., et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 9 (2003) 1106-1110
75. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., and Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005) 44-52
76. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
77. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
78. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 1649-1657
79. Kagansky N., Levy S., Keter D., Rimon E., Taiba Z., Fridman Z., et al. Non-alcoholic fatty liver disease-a common and benign finding in octogenarian patients. Liver Int 24 (2004) 588-594
80. Angulo P., Keach J.C., Batts K.P., and Lindor K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
81. Chitturi S., Weltman M., Farrell G.C., McDonald D., Kench J., Liddle C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36 (2002) 142-149
82. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 179-187
83. Gruber C.J., Tschugguel W., Schneeberger C., and Huber J.C. Production and actions of estrogens. N Engl J Med 346 (2002) 340-352
84. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 23 (2003) 63-69
85. Nadal A., Ropero A.B., Fuentes E., Soria B., and Ripoli C. Estrogen and xenoestrogen actions on endocrine pancreas: from ion channel modulation to activation of nuclear function. Steroids 69 (2004) 531-536
86. Chowen J.A., Frago L.M., and Argente J. The regulation of GH secretion by sex steroids. Eur J Endocrinol 151 (2004) U95-U100
87. Simpson E., Jones M., Misso M., Hewitt K., Hill R., Maffei L., et al. Estrogen, a fundamental palyer in energy homeostasis. J Steroid Biochem Mol Biol 95 (2005) 3-8
88. Chen J.Q., Yager J.D., and Russo J. Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/pathophysiological implications. Biochim Biophys Acta 1746 (2005) 1-17
89. Ricchi M, Bertolotti M, Anzivino C, Carulli L, Canedi I, Bormioli ML, et al., 17beta-estradiol prevents cytoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures. J Gastroenterol Hepatol; in press.
90. Ameen C., and Oscarsson J. Sex difference in hepatic microsomal triglyceride transfer protein expression is determined by the growth hormone secretory pattern in the rat. Endocrinology 144 (2003) 3914-3921
91. Wade G.N., Gray J.M., and Bartness T.J. Gonadal influences on adiposity. Int J Obes 9 (1985) 83-92
92. Jones M.E., Thorburn A.W., Britt K.L., Hewitt K.N., Wreford N.G., Proietto J., et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA 97 (2000) 12735-12740
93. Heine P.A., Taylor J.A., Iwamoto G.A., Lubahn D.B., and Cooke P.S. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 97 (2000) 12729-12734
94. Hewitt K.N., Pratis K., Jones M.E., and Simpson E.R. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 145 (2004) 1842-1848
95. Collet M.E., Smith J.T., and Wertenberger G.E. The effect of estrin upon the basal metabolism rate and the nervous symptoms of ovariectomized women. Am J Obstet Gynecol 34 (1937) 639-656
96. Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003) 2404-2411
97. Pfeilschifter J., Koditz R., Pfohl M., and Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23 (2002) 90-119
98. Guttmann H., Weiner Z., Nikolski E., Ish-Shalom S., Itskovitz-Eldor J., Aviram M., et al. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin Endocrinol (Oxford) 54 (2001) 159-164
99. Roulot D., Degott C., Chazouilleres O., Oberti F., Cales P., Carbonell N., et al. Vascular involvement of the liver in Turner's syndrome. Hepatology 39 (2004) 239-247
100. Ostberg J.E., Thomas E.L., Hamilton G., Attar M.J., Bell J.D., and Conway G.S. Excess visceral and hepatic adipose tissue in Turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. J Clin Endocrinol Metab 90 (2005) 2631-2635
101. Bruno S., Maisonneuve P., Castellana P., Rotmensz N., Rossi S., Maggioni M., et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. Br Med J 330 (2005) 932
102. Ohnishi T., Ogawa Y., Saibara T., Nishioka A., Kariya S., Fukumoto M., et al. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Oncol Rep 13 (2005) 485-489
103. Maffei L., Murata Y., Rochira V., Tubert G., Aranda C., Vazquez M., et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89 (2004) 61-70
104. Holmang A., and Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 146 (1992) 505-510
105. Moran S.A., Patten N., Young J.R., Cochran E., Sebring N., Reynolds J., et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53 (2004) 513-519
106. Moretti C., Frajese G.V., Guccione L., Wannenes F., De Martino M.U., Fabbri A., et al. Androgens and body composition in the aging male. J Clin Endocrinol Metab 28 (2005) 56-64
107. Ohnishi T., Ogawa Y., Saibara T., Nishioka A., Kariya S., Fukumoto M., et al. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients. Oncol Rep 13 (2005) 485-489
108. Makhsida N., Shah J., Yan G., Fisch H., and Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 174 (2005) 827-834
109. Karagiannis A., and Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol 152 (2005) 501-513
110. Lindstedt G., Lundberg P.A., Lapidus L., Lundgren H., Bengtsson C., and Bjorntorp P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 40 (1991) 123-128
111. Haffner S.M., Shaten J., Stern M.P., Smith G.D., and Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT research group. Multiple risk factor intervention trial. Am J Epidemiol 143 (1996) 889-897
112. Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., and McKinaly J.B. Testosterone, sex hormone-binding globulin and the development of type-2 diabetes in middle-aged men: prospective results from the Massachussets male aging study. Diabetes Care 23 (2000) 490-494
113. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Valkonen V.P., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 (2004) 1036-1041
114. Nestler J.E. Insulin resistance effects on sex hormones and ovulation in the polycystic ovary syndrome. In: Reaven G.M., and Laws A. (Eds). Insulin resistance. The metabolic syndrome X (1999), Humana Press, Totowa, NJ 347-365
115. Walker B.R. Steroid metabolism in metabolic syndrome X. Best Pract Res Clin Endocrinol Metab 15 (2001) 111-122
116. Rask E., Olsson T., Soderberg S., Andrew R., Livingstone D.E., Johnson O., et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86 (2001) 1418-1421
117. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
118. De Leo V., la Marca A., and Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24 (2003) 633-637
119. Achard M., and Thiers M.J. Le virilisme plaire et son association a linsuffisance glycolyique (diabete des femmes a barbe). Bull Acad Natl Med 86 (1921) 51-64
120. Ardawi M.S., and Rouzi A.A. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril 83 (2005) 1708-1716
121. Schwimmer J.B., Khorram O., Chiu V., and Schwimmer W.B. Abnormal aminotransferase activity in women with polycystic ovary sndrome. Fertil Steril 83 (2005) 494-496
122. Shepherd Peter.R., and Kahn Barbara.B. Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med 341 (1999) 248-257
123. Saltiel A.R., and Pessin J.E. Insulin signaling pathways in time and space. Trends Cell Biol 12 (2002) 65-71
124. Choudhury J., and Sanyal A.J. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 575-594 [ix]
125. Lonardo A., Lombardini S., Ricchi M., Scaglioni F., and Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 22 (2005) 64-70
126. Vahl T.P., and D'Alessio D.A. Gut peptides in the treatment of diabetes mellitus. Expert Opin Investig Drugs 13 (2004) 177-188
127. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?. Dig Dis 17 (1999) 80-89
128. Gupte P., Amarapurkar D., Agal S., Baijal R., Kulshrestha P., Pramanik S., et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19 (2004) 854-858
129. Tolman K.G., Fonseca V., Tan M.H., and Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 141 (2004) 946-956
130. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
131. Hanley A.J., Williams K., Festa A., Wagenknecht L.E., D'Agostino Jr. R.B., Kempf J., et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 53 (2004) 2623-2632
132. Nannipieri M., Gonzales C., Baldi S., Posadas R., Williams K., Haffner S.M., et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 28 (2005) 1757-1762
133. Jimba S., Nakagami T., Takahashi M., Wakamatsu T., Hirota Y., Iwamoto Y., et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Med 22 (2005) 1141-1145
134. Okamoto M., Takeda Y., Yoda Y., Kobayashi K., Fujino M.A., and Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol 13 (2003) 15-21
135. Silverman J.F., Pories W.J., and Caro J.F. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 24 (1989) 275-302
136. Silverman J.F., O'Brien K.F., Long S., Leggett N., Khazanie P.G., Pories W.J., et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85 (1990) 1349-1355
137. Haukeland J.W., Konopski Z., Linnestad P., Azimy S., Loberg E.M., Haaland T., et al. Abnormal glucose tolorance is a predictor of steatohepatitis and fibrosis in patiens with non-alcoholic fatty liver disease. Scand J Gastroenterol 40 (2005) 1469-1477
138. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
139. Adams L.A., Sanderson S., Lindor K.D., and Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 (2005) 132-138
140. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
141. Trombetta M., Spiazzi G., Zoppini G., and Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 22 (2005) 24-27
142. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., and Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona diabetes study. Diabetes Care 22 (1999) 756-761
143. Targher G., Bertolini L., Poli F., Rodella S., Scala L., Tessari R., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54 (2005) 3541-3546
144. Tilg H., and Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 148-155
145. Marchesini G., Natale S., Manini R., and Agostini F. Review article: the treatment of fatty liver disease associated with the metabolic syndrome. Aliment Pharmacol Ther 22 (2005) 37-39
146. Reynaert H., Geerts A., and Henrion J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther 22 (2005) 890-897
147. Shulman, Caldwell S.H., Chang C.Y., Nakamoto R.K., and Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 595-617
148. Lowell B.B., and Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 307 (2005) 384-387
149. Kashyap S.R., Roman L.J., Lamont J., Masters B.S., Bajaj M., Suraamornkul S., et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 90 (2005) 1100-1105
150. D'alessio Rotella C.M., Pala L., and Mannucci E. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 28 (2005) 746-758
151. Drucker D.J. Glucagon-like peptide-1 and the islet cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144 (2003) 5145-5148
152. Ding X., Saxena N.K., Lin S., Gupta N., and Anania F.A. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43 (2005) 173-181
153. Diehl A.M. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 619-638
154. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53 (2004) S143-S151
155. Diehl A.M., Li Z.P., and Yang S.Q. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54 (2005) 303-306
156. Tobe K., Ogura T., Tsukamoto C., Imai A., Matsuura K., Iwasaki Y., et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. Am J Gastroenterol 94 (1999) 3328-3335
157. Giannini E., Botta F., Cataldi A., Tenconi G.L., Ceppa P., Barreca T., et al. Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C. Hepatogastroenterol 46 (1999) 2422-2425
158. Uygun A., Kadayifci A., Yesilova Z., Erdil A., Yaman H., Saka M., et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 95 (2000) 3584-3589
159. Chitturi S., Farrell G., Frost L., Kriketos A., Lin R., Fung C., et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 36 (2002) 403-409
160. Chalasani N., Crabb D.W., Cummings O.W., Kwo P.Y., Asghar A., Pandya P.K., et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?. Am J Gastroenterol 98 (2003) 2771-2776
161. Liangpunsakul S., and Chalasani N. Relationship between unexplained elevations in alanine aminotransferase and serum leptin in US adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol 38 (2004) 891-897
162. Yki-Jarvinen H., and Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 5 (2005) 287-295
163. Lonardo A., Bagni A., Tarugi P., and Loria P. The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. Eur J Gastroenterol Hepatol 16 (2004) 1043-1050
164. Oral E.A., Ruiz E., Andewelt A., Sebring N., Wagner A.J., Depaoli A.M., et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab 87 (2002) 3110-3117
165. Moran S.A., Patten N., Young J.R., Cochran E., Sebring N., Reynolds J., et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53 (2004) 513-519
166. Javor E.D., Cochran E.K., Musso C., Young J.R., Depaoli A.M., and Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54 (2005) 1994-2002
167. Petersen K.F., Oral E.A., Dufour S., Befroy D., Ariyan C., Yu C., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109 (2002) 1345-1350
168. Javor E.D., Ghany M.G., Cochran E.K., Oral E.A., DePaoli A.M., Premkumar A., et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41 (2005) 753-760
169. Sniderman A.D., Cianflone K., Arner P., Summers L.K., and Frayn K.N. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol 18 (1998) 147-151
170. Maslowska M., Scantlebury T., Germinario R., and Cianflone K. Acute in vitro production of acylation stimulating protein in differentiated human adipocytes. J Lipid Res 38 (1997) 1-11
171. Yesilova Z., Ozata M., Oktenli C., Bagci S., Ozcan A., Sanisoglu S.Y., et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 100 (2005) 842-849
172. Kugelmas M., Hill D.B., Vivian B., Marsano L., and McClain C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38 (2003) 413-419
173. Meier U., and Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem (2004) 1511-1525
174. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
175. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
176. Tsukinoki R., Morimoto K., and Nakayama K. Association between lifestyle factors and plasma adiponectin levels in Japanese men. Lipids Health Dis 4 (2005) 27
177. Lopez-Bermejo A., Botas P., Funahashi T., Delgado E., Kihara S., Ricart W., et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxford) 60 (2004) 256-263
178. Yokoyama H., Hirose H., Ohgo H., and Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 41 (2004) 19-24
179. Sargin H., Sargin M., Gou H., Orcun A., Balolu G., Ozisk M., et al. Is adiponectin level a predictor of nonalcoholic fatty liver disease in nondiabetic male patients?. World J Gastroenterol 11 (2005) 5874-5877
180. Targher G., Bertolini L., Scala L., Poli F., Zenari L., and Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol 61 (2004) 700-703
181. Zou C.C., Liang L., Hong F., Fu J.F., and Zhao Z.Y. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J 52 (2005) 519-524
182. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., and Gorge J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
183. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in non-alcoholic steatoheaptitis. Gut 54 (2005) 117-121
184. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue. Emerging role in non-alcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 273-279
185. Musso G., Gambino R., Biroli G., Carello M., Fagà E., Pacini G., et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatoheaptitis. Am J Gastroenterol 100 (2005) 1-9
186. Musso G., Gambino R., Durazzo M., Biroli G., Carello M., Faga E., et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42 (2005) 1175-1183
187. Vuppalanchi R., Marri S., Kolwankar D., Considine R.V., and Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 39 (2005) 237-242
188. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., et al. Plasma adiponectin in non-alcoholic fatty liver disease is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90 (2005) 3498-3504
189. Sennello J.A., Fayad R., Morris A.M., Eckel R.H., Asilmaz E., Montez J., et al. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 146 (2005) 2157-2164
190. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S.L., and Cooper G.J.S. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 112 (2003) 91-100
191. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazione. Hepatology 38 (2003) 1008-1017
192. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., et al. Induction of adiponectin, a fat-derived antidiabetic and anti-atherogenic factor, by nuclear receptors. Diabetes 52 (2003) 1655-1663